Albrecht Joerg, Fine Lauren Ann, Piette Warren
Department of Medicine, Division of Dermatology, John Stroger Jr. Hospital of Cook County, Administration Bldg., 1900 W Polk Street, Chicago, IL 60612, USA.
Dermatol Clin. 2007 Apr;25(2):233-44, vii. doi: 10.1016/j.det.2007.01.008.
This article discusses ways to recognize and manage lymphomas and pseudolymphomas associated with drug exposure. Over the last 30 years, the classification of pseudolymphomas and lymphomas has undergone significant change, especially following the application of sophisticated immunostaining and gene rearrangement analysis. The term cutaneous pseudolymphomas (CPL) is a nonspecific term for a heterogeneous group of benign reactive T- or B-cell lymphoproliferative processes that simulate cutaneous lymphomas clinically or histologically. While pseudolymphomas are relatively rare diseases, their clinical and histological heterogeneity has led to multiple systems of categorization based on immunological factors, causative agents, presentation, and clinical course.
